Sanofi and the Institut Pasteur create four prestigious awards

SanofiSanofi (EURONEXT: SAN and NYSE: SNY) and the Institut Pasteur announced the creation of the Sanofi-Institut Pasteur Awards to encourage scientific excellence in the service of health.

Four hundred and eighty thousand euro (480,000 €) will support four innovative research projects demonstrating real progress in the life sciences and providing answers to major healthcare problems, more specifically in four fields: neglected tropical diseases, vaccine innovation, drug resistance, and therapeutic approaches to ageing and regenerative medicine.

The jury is composed of seven prestigious members: Prof. Peter C. Agre, John Hopkins University, Baltimore, United States, Nobel Prize in Chemistry 2003, Prof. Elizabeth H. Blackburn, University of California, San Francisco, Nobel Prize in Medicine 2009, Prof. Pascale Cossart, Head of the Bacteria-Cell Interactions Unit, Institut Pasteur, Prof. Alice Dautry, President of the Institut Pasteur, Prof. Depei Liu, Vice President of the Academy of Engineering of China and President of the Chinese Academy of Medical Sciences and the Peking Union Medical College, Dr Robert Sebbag, Vice President, Access to Medicines, Sanofi, and Dr Elias Zerhouni, President, Global R&D, Sanofi.

"With these awards, the Institut Pasteur confirms its commitment to the greater interest by encouraging research, notably in conditions affecting the most vulnerable populations and diseases sharply on the rise in the world," said Alice Dautry, President of the Institut Pasteur.

"I am enthusiastic about this collaborative endeavour with the Institut Pasteur which will promote and support research teams capable of making a real difference in the lives of patients and in key areas of public health," said Elias Zerhouni, President, Global R&D of Sanofi. "The Sanofi-Institut Pasteur Awards follow a long-standing partnership between our two organizations."

Candidates can submit their applications by April 20, 2012. The prices will be awarded in November 2012 at the Institute Pasteur in Paris. For further information: www.sanofiinstitutpasteur-awards.com

Sanofi and the Institut Pasteur have a long history of partnership which reflects Louis Pasteur philosophy which states that "Pure research and applied research are not separate entities. Research and its applications are united together as the fruit of the tree is united with the branch that bears it."

The first partnership emerged through the establishment of the dedicated fund "Fighting Parasitic Diseases" which led to the creation of new research teams. Today, Sanofi also sponsors the Center for Integrative Biology of Emerging Diseases (BIME) and collaborates with the Institut Pasteur in the development of new vaccines against infectious diseases.

About the Institut Pasteur
An internationally renowned center of biomedical research, the Institut Pasteur, created in 1887 by Louis Pasteur, is a recognized private non-profit foundation. Its mission is to contribute to preventing and fighting disease in France and around the world, through scientific and medical research, education, and public health activities. About 2600 individuals work on its campus in Paris. In addition to research in the field of life sciences, a significant part of its work is dedicated to the study of infectious, genetic and neurodegenerative diseases as well as certain cancers. The Institut Pasteur is at the heart of an international network comprising 32 institutes on 5 continents. Since its creation, 10 researchers have received the Nobel Prize in Medicine.

About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Most Popular Now

Novartis rises to second place in 2018 Access to M…

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to ...

MSD is looking for a digital health solution to em…

MSD Lebanon is looking for an external partner to co-create a digital solution that helps oncologists to stay updated with relevant clinical content about cancer. The sol...

Lilly submits New Drug Application to the FDA for …

Eli Lilly and Company (NYSE: LLY) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lasmiditan for the acute...

FDA approves new treatment for patients with acute…

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for t...

New study reveals probiotics do not help children …

Probiotics are a multibillion-dollar industry with marketing claims of being an effective treatment for a multitude of ailments, including diarrhea. However, findings fro...

Merck and Pfizer provide update on avelumab in pla…

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxor...

Sanofi builds focus on rare blood disorders and ca…

Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research...

Abbott recommends rejection of below-market mini-T…

Abbott (NYSE: ABT) received notice of an unsolicited mini-tender offer by Baker Mills LLC (Baker Mills) to purchase up to 60,000 Abbott common shares, representing approx...

Scorpion venom to shuttle drugs into the brain

The Peptides and Proteins lab at the Institute for Research in Biomedicine (IRB Barcelona) has published a paper in Chemical Communications describing the capacity of a s...

AstraZeneca to divest US Synagis rights to Sobi

AstraZeneca has agreed to sell US rights to Synagis (palivizumab) used for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncyt...

Bristol-Myers Squibb awards "Golden Tickets…

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today anno...

Syntropy to unlock the value of scientific data in…

Merck, a leading science and technology company, and software company Palantir Technologies, today announced their intent to form a joint venture under the brand name Syn...